Department of Anaesthesiology, Intensive Care, Emergency and Pain Medicine, University Hospital Würzburg, Würzburg, Germany.
Institute of Experimental Biomedicine, University Hospital Würzburg, Würzburg, Germany; Department of Internal Medicine I, University Hospital Würzburg, Würzburg, Germany.
J Thromb Haemost. 2024 Aug;22(8):2316-2330. doi: 10.1016/j.jtha.2024.05.008. Epub 2024 May 17.
Extracorporeal membrane oxygenation (ECMO) is a lifesaving therapy in patients with acute respiratory distress syndrome (ARDS). Hemostatic complications are frequently observed in patients on ECMO and limit the success of this therapy. Platelets are key mediators of hemostasis enabling activation, aggregation, and thrombus formation by coming in contact with exposed matrix proteins via their surface receptors such as glycoprotein (GP) VI or GPIb/V/IX. Recent research has elucidated a regulatory role of the GPV subunit. The cleaved soluble GPV (sGPV) ectodomain was identified to spatiotemporally control fibrin formation through complex formation with thrombin.
We aimed to decipher the impact of ECMO on platelet phenotype and function, including the role of GPV and plasmatic sGPV.
We recruited 36 patients with ARDS in the wake of COVID-19 pneumonia and performed a longitudinal comparison of platelet phenotype and function in non-ECMO (n = 23) vs ECMO (n = 13) compared with those of healthy controls. Patients were assessed at up to 3 time points (t = days 1-3; t = days 4-6; and t = days 7-14 after cannulation/study inclusion).
Agonist-induced platelet activation was assessed by flow cytometry and revealed decreased GPIIb/IIIa activation and α-granule release in all ARDS patients. During ECMO treatment, agonist-induced δ-granule release continuously decreased, which was independently confirmed by electron microscopy and was associated with a prolonged in vitro bleeding time. GPV expression on the platelet surface markedly decreased in ECMO patients compared with that in non-ECMO patients. Plasma sGPV levels were increased in ECMO patients and were associated with poor outcome.
Our data demonstrate an ECMO-intrinsic platelet δ-granule deficiency and hemostatic dysfunction beyond the underlying ARDS.
体外膜肺氧合(ECMO)是急性呼吸窘迫综合征(ARDS)患者的一种救生疗法。在接受 ECMO 的患者中经常观察到止血并发症,这限制了这种治疗的成功。血小板是止血的关键介质,通过其表面受体(如糖蛋白(GP)VI 或 GPIb/V/IX)与暴露的基质蛋白接触,使血小板激活、聚集和血栓形成。最近的研究阐明了 GPV 亚基的调节作用。已鉴定出切割的可溶性 GPV(sGPV)细胞外结构域通过与凝血酶形成复合物,在时空上控制纤维蛋白的形成。
我们旨在破译 ECMO 对血小板表型和功能的影响,包括 GPV 和血浆 sGPV 的作用。
我们招募了 36 名 COVID-19 肺炎后发生 ARDS 的患者,并对非 ECMO(n=23)与 ECMO(n=13)患者与健康对照组的血小板表型和功能进行了纵向比较。患者在多达 3 个时间点(t=插管/研究纳入后第 1-3 天;t=第 4-6 天;t=第 7-14 天)进行评估。
通过流式细胞术评估激动剂诱导的血小板活化,发现所有 ARDS 患者的 GPIIb/IIIa 活化和α-颗粒释放均降低。在 ECMO 治疗期间,激动剂诱导的δ-颗粒释放持续减少,这通过电子显微镜独立证实,并与体外出血时间延长相关。与非 ECMO 患者相比,ECMO 患者血小板表面的 GPV 表达明显降低。ECMO 患者的血浆 sGPV 水平升高,并与不良预后相关。
我们的数据表明,ECMO 具有内在的血小板 δ-颗粒缺陷和止血功能障碍,超出了潜在的 ARDS。